Pharma Capital
Market: AIM
52-week High/Low: 890.00p / 492.75p
Sector: Pharma & Biotech
Market Cap: 1,011.73M
Address: Pitcairn House, Crown Square, First Avenue, Burton-on-Trent DE14 2WW.

Clinigen Group is a global pharmaceutical and services company with a unique combination of businesses focused on medicines access, delivering the right drug to the right patient at the right time.

The Group consists of five synergistic businesses;
Clinigen Clinical Trial Services is the global market leader in the management and supply of commercial medicines for clinical trials. Clinigen is also the trusted global leader in ethically sourcing and supplying unlicensed medicines to hospital pharmacists and physicians for patients with a high unmet need; through Idis MA (Managed Access) we run early access programs for innovative new medicines; through our Idis GA (Global Access) and Link Healthcare teams we work directly with healthcare providers to enable ethical compliant access to unlicensed medicines on a global basis and local access to niche essential licensed medicines in the AAA region (Asia, Africa and Australasia). Clinigen Specialty Pharmaceuticals acquires global rights, revitalises and markets our own portfolio of niche hospital commercial products.

Clinigen is traded in the ISDX Exchange HERE

Clinigen Group PLC

Interactive graph

col 3
col 4
col 5
col 6

Clinigen Group PLC Snapshot


The combination of businesses we have is unique as we are able to centrally manage treatment access for patients across the clinical trial, licensed and unlicensed routes. In an industry that is typically divided into pharma companies and service businesses, we are the only organisation that can do this globally: through Clinigen SP we market our own portfolio of niche products, and through Idis Managed Access and Clinigen CTS we run access programs for our own and other companies’ portfolios, and manage the supply of commercial medicines for clinical trials. As a specialty pharma company in our own right, we have in-house quality and regulatory teams and resources that are able to support and benefit our Managed Access and Clinical Trial Services businesses.



No one can match our knowledge and expertise of the complex global supply chain environment that is required to get medicines to where they are needed anywhere in the world. We have delivered to customers in more than 130 countries, each with its own unique legal and regulatory environments. Then there are the logistical challenges of ensuring a safe, temperature-controlled, speedy journey from origin to destination – with all the customs and practical issues that come up, which are different in every country. We test every route in and out of a country to make sure it is feasible before taking on a project, and we will only accept a route if it can be used in accordance with UK and local country regulations.



All companies say they have the best people and run a successful business, but we know that we do, because our clients say so. But, we also are highly aware that the patients who ultimately benefit from what we do are invariably very sick, and getting the right drug to them at the right time can be essential in prolonging or improving the quality of their lives.



Our aim when we founded the company in 2010 was to have a turnover of £75 million and EBITDA of 20% by June 2014. We achieved this in 18 months, and, unusually for an AIM-listed company, we have generated profits and paid dividends to our shareholders every year. All of our employees share in the Group’s success by being shareholders themselves.

To achieve our aim, we have built a group of complementary businesses which can operate efficiently in a complex global regulatory environment and which can ensure that precious medicines are delivered securely and effectively, wherever they are needed throughout the product lifecycle. Through four businesses, Clinigen Specialty Pharmaceuticals, Clinigen Clinical Trial Services, Idis Managed Access, and Idis Global Access we acquire, license and revitalise niche, hospital-only critical care medicines, and provide patient access to our own and other pharmaceutical companies’ products, whether to meet unmet medical needs or for use in clinical trials.


Clinigen Clinical Trial Services (CTS):

We use our global expertise, systems and relationships to source and manage the supply of commercial medicines to pharmaceutical companies for use exclusively in clinical trials. This requires excellent knowledge of the global pharmaceutical market, the regulatory processes and customs authorities of countries all over the world, along with a high tech supply chain with guaranteed quality and safety standards that can deliver swiftly.

Clinigen Specialty Pharmaceuticals (SP):

We acquire niche medicines that don’t fit into the portfolio of pharmaceutical companies. These are typically hospital-only treatments for rare or life-threatening diseases, and we specialise in revitalising them – giving medicines a new lease of life, ensuring that products will continue to be marketed and distributed responsibly once they have joined the Clinigen portfolio. All the while, we’re ensuring that patients already using the medicine continue to get the treatment they need, while the company whose product we have acquired can feel confident that its reputation is being well looked after.

Idis Managed Access (MA):

On behalf of pharmaceutical and biotech companies, we manage essential programs that provide access to critical medicines for physicians and their patients all over the world. But what is a Managed Access Program? Known by many terms from ‘expanded access’ and ‘named patient’ to ‘compassionate use’ and ‘early access’, a managed access program enables physicians to access treatments that are not available in their own country for patients with an unmet medical need. Wherever they are, we can deliver treatments quickly, efficiently and, most importantly, ethically.

Idis Global Access (GA):

We work directly with Pharmacists and Physicians around the world to provide ethical compliant access to unlicensed medicines for patients when: a medicine is not yet commercially available, may never be approved locally, experiencing temporary supply problems or is an alternative to discontinued medicines.

We are currently 300+ people, headquartered in Burton-on-Trent in the UK, with offices in London, Weybridge, Surrey UK, Philadelphia, US, and Tokyo, Japan.. With a customer services team who speak over 19 languages between them, our clients from all over the world find us easy to do business with, while physicians and pharmacists find us a valuable source of information about how to access the medicines they need for their patients.



Peter Allen, Non-executive Chairman

Peter joined Clinigen as Non-executive Chairman in August 2012.  He has a wealth of experience on private company and publicly owned company Boards, holding both Executive and Non-executive positions.

He is currently Chairman of Future plc, Chroma Therapeutics Limited and Advanced Medical Solutions Group plc and a Non-executive Director of Oxford Nanopore Technologies Limited and Mecom Group plc.

Previously, he held executive positions with Celltech Group plc, Abacus Group plc and ProStrakan Group plc, Chairman of Proximagen Neuroscience plc and Non-executive Director of TMO Renewables Limited and Scancell Holdings plc.

Peter is Chairman of the Nomination Committee and a member of the Audit and Risk Committee and the Remuneration Committee.


Peter George, Chief Executive Officer

Peter joined Clinigen when it formed in June 2010, he was instrumental in the Group’s flotation on AIM in September 2012 as well as the growth of the Group’s revenues from £21m in FY10 to £123m in FY13.

He is also Director of PharmaPatents Global Limited and Wichtig Publishing Srl. and Non-executive Director of Ergomed plc.

Formerly, CEO of Penn Pharma, Executive Vice-president of Wolters Kluwer Health with responsibility for Europe, Asia and South America and Chief Operating Officer of Unilabs Clinical Trials International Limited.


Shaun Chilton, Group Deputy CEO

Shaun has day-to-day oversight of and responsibility for the operating businesses within the Group.

He leads the strategic planning process and is responsible for ensuring the business meets its key performance indicators. Shaun joined Clinigen in January 2012 from KnowledgePoint360 Group, a global pharmaceutical information and services operation, where he was President of a number of operating divisions and a member of the executive management team.

He has 20 years’ experience in the industry across a range of disciplines, including commercial, strategic, operational and sales and marketing roles for companies such as Pfizer and Sanofi.


Martin Abell, Chief Financial Officer

Martin joined Clinigen in August 2015 as CFO Elect.
Before joining Clinigen, Martin worked at the FTSE250 recruitment group Hays plc. At Hays Martin spent the first part of his career as Head of Investor Relations and M&A, and was later appointed Finance Director for the Continental Europe and Rest of World division which operated across 21 countries with revenues of over £1 billion.  Previously, Martin held several financial roles at the FTSE100 logistics group, Exel plc (now part of Deutsche Post) including Financial Controller of two of the UK divisions. He is a qualified Chartered Accountant, having trained at PwC in the M&A Transaction Services team.


John Hartup, Non-Executive Director

John joined Clinigen in May 2011.  He has over 30 years’ experience as a corporate lawyer dealing with corporate finance and commercial contract issues across a number of industries.

John was formerly managing partner at Ricksons LLP and subsequently became a partner at DWF LLP upon that firm’s acquisition of Ricksons.John is a Director of Wichtig Publishing Srl. and a Non-executive Director of Ellis Pharma Limited and Creo Pharma Limited. Formerly was Non-executive Director of Mitre Group Limited.

John is Chairman of the Audit and Risk Committee and a member of the Remuneration Committee and Nomination Committee.


Ian Nicholson, Non-Executive Director

Ian joined Clinigen as Non-executive Director in September 2012. Ian has considerable experience as a Non-executive Director, he currently holds positions on the Boards of Symphogen AS, Consort Medical plc and Bioventix plc, where he is the Non-executive Chairman.

Ian is also a member of the investment committee at Cancer Research UK Pioneer Fund, Chief Executive Officer of F2G Limited, Director of Casewell Consulting Limited and an Operating Partner at Advent Life Sciences LLP.

Formerly, Ian held positions at Chroma Therapeutics Limited, Celltech Group plc and Oxford Asymmetry International plc.

Ian is Chairman of the Remuneration Committee and a member of the Audit and Risk Committee and the Nomination Committee.

General enquiries 
Tel:+44 (0) 1283 495 010

Product enquiries
Tel: +44 (0) 1283 494 340



Clinigen, Pitcairn House, Crown Square, First Avenue, Burton-on-Trent, Staffordshire, DE14 2WW

Tel:+44 (0) 1283 495 010

[email protected]



Clinigen CTS, Pitcairn House, Crown Square, First Avenue, Burton-on-Trent, Staffordshire, DE14 2WW

Tel: +44 (0) 1283 495 010

Fax: +44 (0) 1283 495 011



Clinigen CTS Inc., Three Crescent Drive, Suite 110, Navy Yard Corporate Center, Philadelphia, PA 19112

Tel: +1 (215) 558 7001

Fax: +1 (215) 336 0705

Nominated Advisor
Michael Meade
Numis Securities Limited

The London Stock Exchange Building
10 Paternoster Square
Tel: +44 (0) 20 7260 1000

Joint Broker
James Black
Numis Securities Limited

The London Stock Exchange Building
10 Paternoster Square
Tel: +44 (0) 20 7260 1000

Joint broker
James Steel
Peel Hunt LLP

Moor House
120 London Wall
Tel: +44 (0) 20 7418 8900

Legal Advisor
Addleshaw Goddard LLP

Milton Gate
60 Chiswell Street

PriceWaterhouseCoopers LLP

Cornwall Court
19 Cornwall Street
B3 2DT

Equiniti Limited

Aspect House
Spencer Road
West Sussex
BN99 6DA

Media relations
Melanie Toyne-Sewell
Instinctif Partners Limited

65 Gresham Street
Tel: +44 (0) 20 7457 2020
Email: [email protected]

Clinigen Group PLC Timeline

View All

Market Reports Including CLIN


Executive video interviews


© biotech Capital 2017

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.